ArticleJournal of ophthalmic inflammation and infection2021
Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination.
Article in Journal of ophthalmic inflammation and infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 80 citations in OpenAlex.
- Vogt-Koyanagi-Harada disease recurrence after laser treatment: A case report.The Journal of international medical research · 2026Article
- Seasonal Variations of Vogt-Koyanagi-Harada Disease in Japan: A Study on Long-Term Trends and the Influence of Coronavirus Disease 2019 (COVID-19).Ophthalmology science · 2026Article
- Unilateral Anterior Scleritis Following the Booster Shot of Inactivated COVID-19 (Sinopharm) Vaccine in a 52-Year-Old Woman: A Case Report.Case reports in rheumatology · 2024Article
- Reactivation of previously controlled Vogt-Koyanagi-Harada disease more than 46 years following COVID-19 vaccination: a case study.The Journal of international medical research · 2024Article
- Long-term follow-up of a young male who developed acute macular neuroretinopathy following COVID-19 vaccination.Clinical case reports · 2023Article
- Possible association between vaccination against SARS-CoV-2 and recurrence of macular edema due to branch retinal vein occlusion: a case report.The Journal of international medical research · 2023Article
- Vogt-Koyanagi-Harada Disease and COVID.Journal of clinical medicine · 2023Review
- Ocular manifestations following COVID-19 vaccination.Journal of ophthalmic inflammation and infection · 2023Article
- Tubulointerstitial nephritis and uveitis syndrome (TINU) following COVID-19 vaccination.American journal of ophthalmology case reports · 2023Article
- Epidemic retinitis during the COVID-19 pandemic.Indian journal of ophthalmology · 2023Observational
- A COVID-19 perspective of Vogt-Koyanagi-Harada disease.Indian journal of ophthalmology · 2023Article
- Uveitis including Vogt-Koyanagi-Harada syndrome following inactive covid-19 vaccination: a case series.Journal of ophthalmic inflammation and infection · 2023Article
- Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature.Journal of ophthalmic inflammation and infection · 2023Article
- Navigating Coronavirus Disease 2019 Vaccination and Uveitis: Identifying the Rates and Risk of Recurrent Uveitis after Coronavirus Disease Vaccination.Ophthalmology · 2023Article
- Posterior ocular manifestations following BNT162b2 mRNA COVID-19 vaccine: a case series.International ophthalmology · 2023Article
- Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination.Journal francais d'ophtalmologie · 2023Article
- Vogt-Koyanagi-Harada syndrome in the setting of COVID-19 infection.Clinical case reports · 2023Article
- Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?Vaccines · 2023Review
- The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review.Vaccines · 2022Review
- Acute panuveitis after COVID-19 mRNA booster vaccination following cataract surgery.American journal of ophthalmology case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background/purposeVogt-Koyanagi-Harada (VKH) disease is a primary stromal choroiditis with bilateral granulomatous panuveitis. If initial-onset VKH is treated early and relentlessly the disease can be controlled and even "cured" in a substantial number of cases. We are reporting on a patient treated early and in a sustained fashion who was inflammation free for seven years but who presented a reactivation 6 weeks after the second dose of anti-SARS-CoV-2 vaccination. CASE REPORT: A 43-year-old woman presented with severe initial-onset VKH disease which was brought under control using steroidal and non-steroidal Immunosuppression (mycophenolic acid and cyclosporine) with additional infliximab infusions because of the persistence of subclinical choroiditis identified on ICGA. Under infliximab alone disease had been inflammation free with no subclinical disease and absence of sunset glow fundus for 6 years. However, following anti-SARS-CoV-2 vaccination, severe resurgence of the disease occurred with exudative retinal detachments. Disease was rapidly brought again under control with oral prednisone (1 mg/kg) therapy and a new loading scheme of infliximab therapy.
conclusionVKH disease results from an autoimmune process directed against melanocyte associated antigens which can be controlled when early and sustained immunosuppressive treatment is introduced. It seems that anti-SARS-CoV-2 vaccination can be at the origin of reactivation of long-time controlled disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.